Advertisement
Advertisement
U.S. Markets open in 1 hr 3 mins
Advertisement
Advertisement
Advertisement
Advertisement

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.42-0.50 (-2.79%)
At close: 04:00PM EST
17.09 -0.33 (-1.89%)
Pre-Market: 07:45AM EST
Advertisement
Full screen
Loading interactive chart...
  • GuruFocus.com

    Resonant Capital Advisors, LLC Buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National ...

    Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.

  • Motley Fool

    5 Value Stocks That Can Make You Richer in 2022

    For more than a decade, growth stocks have been the talk of Wall Street. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022.

  • Business Wire

    Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

    ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c

Advertisement
Advertisement